UAE Biobanks Market Report 2023 to 2030

UAE Biobanks Market Analysis

$ 3999

The UAE Biobanks Market was valued at $383.70 Mn in 2023 and is predicted to grow at a CAGR of 9.80% from 2023 to 2030, to $738.26 Mn by 2030. The key drivers of this industry include personalized medicine, increasing biomedical research, and the rising prevalence of chronic disease. The industry is primarily dominated by players such as Thermo Fisher Scientific, Merck KGaA, QIAGEN, and Tecan Group among others.

ID: IN10AEHS058 CATEGORY: Healthcare Services GEOGRAPHY: UAE AUTHOR: Aashwi Mehta

Buy Now

UAE Biobanks Market Executive Summary

The UAE Biobanks Market was valued at $383.70 Mn in 2023 and is predicted to grow at a CAGR of 9.80% from 2023 to 2030, to $738.26 Mn by 2030.

A biobank is a curated collection of mainly human biological samples and related data systematically organized for research purposes. These facilities play a crucial role in medical research, supporting various contemporary studies such as genomics and personalized medicine. The types of samples and information gathered vary based on each biobank's specific objectives. For instance, some biobanks focus on specific diseases like cancer, while others are population-based, comprising samples and data from individuals within a particular demographic or geographic area.

In 2023, the UAE unveiled its inaugural robotic biobank, capable of managing up to 7 Mn specimens, positioning it among the world's largest biobanks in terms of sample capacity. Established by the Department of Health – Abu Dhabi (DoH) and M42, the Abu Dhabi Biobank will store 100,000 cord blood samples and 5 Mn human samples. The market is driven by significant factors like personalized medicine, increasing biomedical research, and the rising prevalence of chronic disease. However, infrastructure limitations, public awareness and trust, and data privacy concerns restrict the growth and potential of the market.

Prominent players in this field include Thermo Fisher Scientific, Merck KGaA, QIAGEN, and Tecan Group among others.

UAE Biobanks Market Report 2023 to 2030

Market Dynamics

Market Growth Drivers

Personalized Medicine: Investments in biobanks in the UAE aim to propel personalized medicine and medical research through the utilization of human tissues and stem cells. This serves as a significant market driver by fostering advancements in healthcare innovation and supporting tailored medical treatments based on individual genetic and biological profiles.

Increasing Biomedical Research: Rising biomedical research and drug discovery in the UAE are boosting demand for high-quality biological samples stored in biobanks, driving market growth.

Rising Prevalence of Chronic Disease: Research conducted among UAE University students found that 23.0% reported having at least one chronic disease, with obesity, diabetes, and asthma being the most common. This data underscores the need for biobanks in the UAE to collect and store biological samples for studying chronic diseases prevalent in the population, thereby driving market demand.

Market Restraints

Infrastructure Limitations: The development and upkeep of sophisticated infrastructure required for storing, handling, and processing biological samples pose significant financial and logistical challenges. This acts as a market restraint for the biobank sector in the UAE due to the substantial investment needed and ongoing operational costs, which can deter potential investors and stakeholders from entering or expanding in the market.

Public Awareness and Trust: Building public trust and awareness about the benefits and ethical considerations of biobanking is crucial but can be a slow and complex process, posing a market restraint for the biobank sector in the UAE.

Data Privacy Concerns: Ensuring participant data protection and compliance with global data privacy standards presents a notable challenge. This poses a market restraint for the biobank sector in the UAE due to the complexities involved in meeting stringent regulatory requirements and maintaining trust among stakeholders, potentially impeding operational efficiency and growth.

Regulatory Landscape and Reimbursement Scenario

The Department of Health (DoH) Abu Dhabi is the primary regulatory body responsible for setting policies and licensing requirements for biobanks in Abu Dhabi. Biobanks are required to obtain approvals and licenses from the DoH and other relevant authorities. On a federal level, the Ministry of Health and Prevention (MoHAP) oversees the regulation of human genome use, including genetic screening and biobanking, throughout the UAE under Federal Law by Decree No. (49) of 2023.

Competitive Landscape

Key Players

Here are some of the major key players in the UAE Biobanks Market:

Thermo Fisher Scientific
Merck KGaA
QIAGEN
Tecan Group
Becton, Dickinson and Company
Hortman Stem Cell Laboratory
Avantor
Smart Cells
Future Health
Bio-Techne Corporation

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UAE Biobanks Market Segmentation

By Product and Service

Equipment
Consumables
Services

By Sample Type

Blood Products
Human Tissues
Nucleic Acids
Others

By Application

Regenerative Medicine
Life Science Research
Clinical Research
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.